S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
3 Secrets To Consistent Trading Success (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
3 Secrets To Consistent Trading Success (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
3 Secrets To Consistent Trading Success (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
3 Secrets To Consistent Trading Success (Ad)pixel
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
What To Do With Your Trades Today (Ad)pixel
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Many electric vehicles to lose big tax credit with new rules
NYSE:BHVN

Biohaven - BHVN Stock Forecast, Price & News

$13.66
-0.02 (-0.15%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$13.32
$14.01
50-Day Range
$12.94
$19.20
52-Week Range
$5.54
$20.57
Volume
1.05 million shs
Average Volume
1.01 million shs
Market Capitalization
$931.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.75

Biohaven MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
256.9% Upside
$48.75 Price Target
Short Interest
Healthy
10.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Biohaven in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($4.30) to ($3.92) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

545th out of 1,004 stocks

Pharmaceutical Preparations Industry

257th out of 489 stocks


BHVN stock logo

About Biohaven (NYSE:BHVN) Stock

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial to treat spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in Sept 2022. The company was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Stock News Headlines

Analysts Set Biohaven Ltd. (NYSE:BHVN) Target Price at $48.75
The Market Crash Shield is A.I.
Are you using the best technology to dominate April markets? This A.I. has traders doubting their methods. Attend This Live (FREE) A.I. Market Training. pixel
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

BHVN Company Calendar

Last Earnings
11/08/2021
Today
3/31/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Previous Symbol
NASDAQ:BHVN
Phone
N/A
Fax
N/A
Employees
928
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.75
High Stock Price Forecast
$148.50
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+256.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-570,280,000.00
Net Margins
-108.04%
Pretax Margin
-40.15%

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$7.90 per share

Miscellaneous

Free Float
59,754,000
Market Cap
$931.75 million
Optionable
Optionable
Beta
1.12

Key Executives

  • Dr. Vladimir Coric M.D. (Age 51)
    Chairman & CEO
  • Mr. Matthew Buten (Age 61)
    Chief Financial Officer
  • Mr. George C. ClarkMr. George C. Clark (Age 38)
    VP & Chief Accounting Officer
  • Dr. Bruce D. Car DACVP (Age 61)
    Ph.D., Chief Scientific Officer
  • Ms. Jennifer Porcelli
    VP of Investor Relations
  • Mr. Warren Volles
    Gen. Counsel & Chief Legal Officer
  • Mr. Clifford Bechtold M.S.
    Chief Compliance Officer
  • Ms. Kimberly GentileMs. Kimberly Gentile (Age 56)
    Sr. VP of Clinical Operations
  • Mr. John TiltonMr. John Tilton (Age 54)
    Chief Commercial Officer of Rare Diseases
  • Mr. Chris Barrett
    Sr. VP of Commercial Strategy, Common Disease













BHVN Stock - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price forecast for 2023?

9 brokerages have issued twelve-month price objectives for Biohaven's stock. Their BHVN share price forecasts range from $21.00 to $148.50. On average, they anticipate the company's stock price to reach $48.75 in the next twelve months. This suggests a possible upside of 256.9% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2023?

Biohaven's stock was trading at $13.88 at the start of the year. Since then, BHVN shares have decreased by 1.6% and is now trading at $13.66.
View the best growth stocks for 2023 here
.

Are investors shorting Biohaven?

Biohaven saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 5,940,000 shares, a decrease of 7.2% from the February 28th total of 6,400,000 shares. Based on an average daily trading volume, of 996,300 shares, the days-to-cover ratio is presently 6.0 days. Approximately 10.3% of the shares of the stock are short sold.
View Biohaven's Short Interest
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) announced its quarterly earnings results on Monday, November, 8th. The company reported ($2.63) earnings per share for the quarter, missing analysts' consensus estimates of ($2.40) by $0.23. The firm had revenue of $135.74 million for the quarter, compared to the consensus estimate of $128.40 million. The business's revenue was up 668.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($3.27) earnings per share.

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an initial public offering on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

What is Biohaven's stock symbol?

Biohaven trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biohaven's stock price today?

One share of BHVN stock can currently be purchased for approximately $13.66.

How much money does Biohaven make?

Biohaven (NYSE:BHVN) has a market capitalization of $931.75 million and generates $462.51 million in revenue each year. The company earns $-570,280,000.00 in net income (profit) each year or ($14.25) on an earnings per share basis.

How many employees does Biohaven have?

The company employs 928 workers across the globe.

How can I contact Biohaven?

Biohaven's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The official website for the company is www.biohavenpharma.com. The company can be reached via email at jennifer.porcelli@biohavenpharma.com.

This page (NYSE:BHVN) was last updated on 4/1/2023 by MarketBeat.com Staff